Nancy Grygiel serves as senior vice president and chief compliance officer, responsible for Amgen’s Compliance, Global Privacy, and Trade organization. Grygiel joined Amgen in 2015 as vice president of Compliance, responsible for overseeing Amgen’s healthcare and anti-corruption compliance programs in all markets. In addition, Grygiel has been accountable for reporting on the status and effectiveness of the program’s elements, and ongoing activities to Amgen’s CEO operating teams, and to the company’s Corporate Responsibility and Compliance Committee (CRCC), on an ongoing basis.
Prior to joining Amgen, Grygiel served as vice president, Compliance, at Allergan. In that role, she was responsible for the implementation and execution of the corporate compliance program’s global strategy. In addition, Grygiel led cross-functional compliance-related efforts and served as an advisor to the corporate audit function on Foreign Corrupt Practices Act and other applicable in-country healthcare laws and regulations.
Prior to her time at Allergan, Grygiel held positions of increasing responsibility at Mylan Pharmaceuticals, where she developed and established the export controls and international compliance program, as a result of the company’s rapid global expansion in 2007.
Earlier in her career, Grygiel worked in the legal field with a focus on international laws, transnational business transactions and export-control laws. She also held in-house legal roles within the telecommunications industry in her home country of Argentina.
Grygiel has a law degree from Buenos Aires University and a Master of Laws degree (LL.M) from Georgetown University Law Center.
What is Nancy A. Grygiel's net worth?
The estimated net worth of Nancy A. Grygiel is at least $2.85 million as of May 3rd, 2024. Ms. Grygiel owns 9,883 shares of Amgen stock worth more than $2,845,019 as of November 21st. This net worth evaluation does not reflect any other assets that Ms. Grygiel may own. Learn More about Nancy A. Grygiel's net worth.
How do I contact Nancy A. Grygiel?
Has Nancy A. Grygiel been buying or selling shares of Amgen?
Nancy A. Grygiel has not been actively trading shares of Amgen over the course of the past ninety days. Most recently, Nancy A. Grygiel sold 2,117 shares of the business's stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $313.09, for a transaction totalling $662,811.53. Following the completion of the sale, the senior vice president now directly owns 9,883 shares of the company's stock, valued at $3,094,268.47. Learn More on Nancy A. Grygiel's trading history.
Who are Amgen's active insiders?
Are insiders buying or selling shares of Amgen?
During the last year, insiders at the medical research company sold shares 2 times. They sold a total of 4,213 shares worth more than $1,235,082.41. The most recent insider tranaction occured on May, 3rd when SVP Nancy A Grygiel sold 2,117 shares worth more than $662,811.53. Insiders at Amgen own 0.7% of the company.
Learn More about insider trades at Amgen. Information on this page was last updated on 5/3/2024.
